Overview High Dose Ascorbic Acid for Plasma Cell Disorders Status: Recruiting Trial end date: 2021-08-31 Target enrollment: Participant gender: Summary This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma. Phase: Phase 1 Details Lead Sponsor: Michael TomassonYogesh JethavaCollaborator: University of IowaTreatments: Ascorbic AcidMelphalan